BioSpace News Archive

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2022.

Bruker Corporation announced financial results for its second quarter and for the six months ended June 30, 2022.

Glaukos Corporation announced that it has received 510 clearance from the U.S. Food and Drug Administration for the iStent infinite® Trabecular Micro-Bypass System indicated for use in a standalone procedure to reduce elevated intraocular pressure in patients with primary open-angle glaucoma uncontrolled by prior medical and surgical therapy.

KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the second quarter ended June 30, 2022.

McKesson Corporation (NYSE: MCK) has released its fiscal 2023 first-quarter financial results.

Bio-Rad Laboratories, Inc. announced that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A., a Warsaw, Poland, for a total consideration of up to $170 million, consisting of approximately $100 million in cash, and up to $70 million in future milestone payments.

DexCom, Inc. announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 10:30am.

Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab and the modeling simulation of the impact of ApoE4 genotype on the incidence of amyloid-related imaging abnormalities.

Cirrus Dx, Inc., an infectious disease diagnostics and laboratory company, announces the acquisition of Dascena Inc.'s Houston-based laboratory business, Dascena Labs, LLC.

Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 27,500 shares of common stock of the company and 14,500 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company.